Affiliations 

  • 1 School of Pharmacy, University of Nottingham, University Park, Nottingham NG7 2RD, UK
  • 2 School of Pharmacy, University of Nottingham Malaysia, Jalan Broga, Semenyih 43500, Selangor, Malaysia
  • 3 Department of Pharmaceutics, Hygia Institute of Pharmaceutical Sciences and Research, Lucknow, India
  • 4 Department of Pharmaceutics, College of Pharmacy, Jazan University, Jazan, Kingdome of Saudi Arabia
  • 5 Department of Pharmacy, Royal College of Medicine Perak, Universiti Kuala Lumpur, Ipoh, Malaysia
  • 6 Department of Pharmacy, Palamu Institute of Pharmacy, Chianki, Jharkhand 822102, India
Curr Pharm Des, 2023;29(36):2853-2866.
PMID: 37946351 DOI: 10.2174/0113816128266398231027100119

Abstract

Many methods, including solid dispersion, micellization, and inclusion complexes, have been employed to increase the solubility of potent drugs. Beta-cyclodextrin (βCD) is a cyclic oligosaccharide consisting of seven glucopyranoside molecules, and is a widely used polymer for formulating soluble inclusion complexes of hydrophobic drugs. The enzymatic activity of Glycosyltransferase or α-amylase converts starch or its derivatives into a mixture of cyclodextrins. The βCD units are characterized by α -(1-4) glucopyranose bonds. Cyclodextrins possess certain properties that make them very distinctive because of their toroidal or truncated cage-like supramolecular configurations with multiple hydroxyl groups at each end. This allowed them to encapsulate hydrophobic compounds by forming inclusion complexes without losing their solubility in water. Chemical modifications and newer derivatives, such as methylated βCD, more soluble hydroxyl propyl methyl βCD, and sodium salts of sulfobutylether-βCD, known as dexolve® or captisol®, have envisaged the use of CDs in various pharmaceutical, medical, and cosmetic industries. The successful inclusion of drug complexes has demonstrated improved solubility, bioavailability, drug resistance reduction, targeting, and penetration across skin and brain tissues. This review encompasses the current applications of β-CDs in improving the disease outcomes of antimicrobials and antifungals as well as anticancer and anti-tubercular drugs.

* Title and MeSH Headings from MEDLINE®/PubMed®, a database of the U.S. National Library of Medicine.